Allarity receives notice of allowance from USPTO

Allarity (ALLR) announced that the United States Patent and Trademark Office has issued a notice of allowance for its patent application covering the company’s DRP companion diagnostic specific to stenoparib. Importantly, this notice of allowance covers multiple claims and represents a major step in Allarity’s global strategy to expand and protect the commercial potential of stenoparib when selecting patients using its proprietary stenoparib DRP test. The patent is expected to be formally granted within three months, subject to standard administrative procedures and would provide exclusivity at least into 2039 for stenoparib when used in concert with the DRP as a companion diagnostic.